Literature DB >> 7504047

Purification of the major substrate for palmitoylation in rat adipocytes: N-terminal homology with CD36 and evidence for cell surface acylation.

A Jochen1, J Hays.   

Abstract

We previously reported that incubating rat adipocytes with [3H]palmitate predominantly labeled an 85-kDa protein. The labeling was more intensive in the presence of insulin and had characteristics consistent with covalent fatty acylation (Jochen et al. 1991. Biochem. Biophys. Res. Commun. 177: 797-801). In order to determine the significance of this finding we purified the 85-kDa protein, determined its N-terminal sequence, and further characterized its interactions with long-chain fatty acids. The [3H]palmitate-labeled 85-kDa protein was purified from rat adipocyte membranes using the following sequence of procedures: i) affinity chromatography with wheat germ agglutinin-agarose, ii) ion exchange chromatography with DEAE-Sepharose, and iii) SDS-polyacrylamide gel electrophoresis. The resulting labeled protein was sequenced through 30 amino acid residues. With the exception of one conserved substitution, the sequence was identical to CD36 (platelet membrane glycoprotein IV). Further characterization of the 85-kDa protein revealed it was heavily N-glycosylated and possessed a cell surface domain. Labeling of the 85-kDa protein with palmitate was compared in control cells, insulin-treated cells, and cells whose energy was depleted with 2,4-dinitrophenol. Insulin and energy depletion increased labeling approximately 3-fold and 12-fold, respectively. Labeling performed in the presence of energy depletion possessed all of the characteristics of covalent protein acylation. In addition, there was a close association between the ability of energy depletion to increase labeling of the 85-kDa protein and its ability to inhibit depletion of [3H]palmitate from the extracellular incubation media. These results suggest that the major substrate for fatty acylation in adipocytes is a cell surface membrane protein related to CD36 and that this acylation has the unusual properties of being independent of intracellular metabolic energy and of occurring on an exofacial epitope of the protein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504047

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

Review 1.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

2.  Point mutations in bovine opsin can be classified in four groups with respect to their effect on the biosynthetic pathway of opsin.

Authors:  G L DeCaluwé; W J DeGrip
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

3.  Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet.

Authors:  D E Greenwalt; S H Scheck; T Rhinehart-Jones
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

4.  Intracellular pH in adipocytes: effects of free fatty acid diffusion across the plasma membrane, lipolytic agonists, and insulin.

Authors:  V N Civelek; J A Hamilton; K Tornheim; K L Kelly; B E Corkey
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 5.  Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins.

Authors:  J J Luiken; F G Schaap; F A van Nieuwenhoven; G J van der Vusse; A Bonen; J F Glatz
Journal:  Lipids       Date:  1999       Impact factor: 1.646

Review 6.  Putative Role of Protein Palmitoylation in Cardiac Lipid-Induced Insulin Resistance.

Authors:  Francesco Schianchi; Jan F C Glatz; Artur Navarro Gascon; Miranda Nabben; Dietbert Neumann; Joost J F P Luiken
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

7.  Proteomic analysis of protein palmitoylation in adipocytes.

Authors:  Wenying Ren; Ulupi S Jhala; Keyong Du
Journal:  Adipocyte       Date:  2013       Impact factor: 4.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.